AMRI boosts revenue by 42 percent

When Bill Marth took over as CEO at Albany Molecular Research Inc., his main focus was to increase revenue and elevate the profile of the drug development company. Three years later, he is coming off of a strong 2016 when revenue grew by 42 percent to $570.5 million, following a string of acquisitions in New Mexico, Spain and Italy. The Albany, New York, company, best known for discovering the active ingredient in the allergy medication Allegra, has expande d its portfolio to include more than 240…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news